Skip to main content
BrainCited

Bacopa monnieri for Memory Loss

A

Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dbacopa\u002Dmonnieri\u0026condition\u003Dmemory\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

The Bottom Line

Multiple systematic reviews consistently report small-to-moderate improvements in memory recall and processing speed after 8-12 weeks of Bacopa use. A network meta-analysis found high-dose Bacopa (600+ mg/day) significantly improved working and short-term memory.

Key Study Findings

Systematic Review
Cholinesterase Inhibitors from Plants and Their Potential in Alzheimer's Treatment: Systematic Review.
Dose: None vs: None Outcome: Cholinesterase inhibition and cognitive improvement Effect: None None

Population: In vivo animal models of AD

Other
Differential Alterations in the Expression of AMPA Receptor and Its Trafficking Proteins in the Hippocampus …
Dose: 200 mg/kg body weight vs: Rotenone-PD mice without BME Outcome: Recognition memory and AMPA receptor expression Effect: None None

Population: Rotenone-induced Parkinson's disease mouse model

Review
Comprehensive Insights into Pathophysiology of Alzheimer's Disease: Herbal Approaches for Mitigating Neurodegeneration.
Dose: None vs: None Outcome: Cognitive decline Effect: None None

Population: Alzheimer's disease patients

Other
Exploring the immunomodulatory potential of Brahmi (Bacopa monnieri) in the treatment of invasive ductal carcinoma.
Dose: Bacopa monnieri (Brahmi) vs: None Outcome: Immunomodulatory effects in breast cancer Effect: None None

Population: Retracted publication - invasive ductal carcinoma

In Vitro
Bacopa monnieri: A promising herbal approach for neurodegenerative disease treatment supported by in silico and …
Dose: Bacopa monnieri phytocompounds vs: Standard AChE inhibitors Outcome: AChE inhibition and neuroprotection Effect: None None

Population: In silico/in vitro NDD study

In Vitro
Bacopa monnieri reduces Tau aggregation and Tau-mediated toxicity in cells.
Dose: None vs: None Outcome: oxidative stress markers Effect: None None

Population: None

Key Statistics

22

Studies

1800

Participants

Positive

A

Grade

Referenced Papers

International journal of … 2023 13 citations
The Senior care … 2021 2 citations

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Commonly Used Dosages

general:
300-600 mg/day standardized to 50% bacosides
memorysupport:
300 mg/day for minimum 8-12 weeks

Upper limit: Not established; well-tolerated up to 600 mg/day in trials

Dosages Studied in Research

Dosage Duration Effect N
None -- Positive --
200 mg/kg body weight -- Positive --
None -- Mixed --
Bacopa monnieri (Brahmi) -- Positive --
Bacopa monnieri phytocompounds -- Positive --
None -- Mixed --
None -- Positive --
None 72 weeks Positive --

Best taken: With meals; effects require 8-12 weeks of consistent use

Safety & Side Effects

Reported Side Effects

  • Gastrointestinal discomfort (nausea, cramping, diarrhea)
  • Dry mouth
  • Fatigue in some individuals
  • Mild sedation at higher doses

Known Interactions

  • Thyroid medications (may increase thyroid hormone levels)
  • Anticholinergic drugs (opposes cholinergic enhancement)
  • Sedative medications (additive CNS depression)
  • Calcium channel blockers (may enhance blood pressure lowering)

Tolerable upper intake: Not established; well-tolerated up to 600 mg/day in trials

Always consult your healthcare provider before starting any supplement.

Frequently Asked Questions

Does Bacopa monnieri help with Memory Loss?
Based on 22 studies with 1,800 participants, there is strong evidence from multiple clinical trials that Bacopa monnieri may support Memory Loss management. Our evidence grade is A (Strong Evidence).
How much Bacopa monnieri should I take for Memory Loss?
Studies have used various dosages. A commonly studied range is 300-600 mg/day standardized to 50% bacosides. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Bacopa monnieri?
Reported side effects may include Gastrointestinal discomfort (nausea, cramping, diarrhea), Dry mouth, Fatigue in some individuals, Mild sedation at higher doses. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Bacopa monnieri and Memory Loss?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 22 peer-reviewed studies with 1,800 total participants. The overall direction of effect is positive.

Related Evidence

FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. The products and information on this website are not intended to diagnose, treat, cure, or prevent any disease. The evidence grades presented are based on our analysis of published peer-reviewed research and do not constitute medical advice. Always consult your healthcare provider before starting any supplement regimen.